Lam Research Corporation - 10-Q Summary
Business Context and Reporting Period
Lam Research Corporation is a leading supplier of thin film selective removal equipment for semiconductor wafer fabrication. This report covers the quarterly period ended March 31, 2002, and the nine-month period ended on that date. The company operates in a cyclical industry heavily dependent on semiconductor manufacturers' capital spending, which has contracted significantly in the current fiscal year.
Key Financial Metrics
| Metric | Three Months Ended Mar 31, 2002 | Nine Months Ended Mar 31, 2002 |
|---|---|---|
| Total Revenue | $164.1 million | $762.9 million |
| Gross Margin | $55.0 million (33.5%) | $199.7 million (26.2%) |
| Operating Income (Loss) | ($22.4 million) | ($112.5 million) |
| Net Income (Loss) | $1.6 million | ($59.0 million) |
| Diluted EPS | $0.01 | ($0.47) |
| Cash & Equivalents | $130.1 million | $130.1 million (Ending Balance) |
| Short-term Investments | $700.4 million | $700.4 million (Ending Balance) |
| Total Debt (Current + Long-term) | $666.7 million | $666.7 million (Contractual Obligations) |
Note: Net income for the quarter includes a non-taxable gain of $16.8 million from equity derivative contracts. Operating loss for the nine months includes significant restructuring and litigation charges.
Material Changes vs. Prior Period
- Revenue Decline: Revenue decreased 64.7% for the quarter and 33.9% for the nine months compared to the prior year, driven by reduced capital spending by semiconductor manufacturers.
- Margin Compression: Gross margin percentage dropped from 43.6% to 33.5% (quarter) and 43.8% to 26.2% (nine months) due to excess capacity, inventory write-downs ($24.1 million), and a patent litigation settlement ($38.8 million).
- Restructuring Charges: The company recorded $47.2 million in restructuring charges for the nine months ended March 31, 2002, related to three separate plans (June, September, and December 2001) involving headcount reductions and facility consolidations.
- Derivative Gains: A significant non-operating gain of $17.7 million was recorded for the nine months due to changes in the fair value of equity derivative contracts indexed to the company's stock.
Guidance, Outlook, and Risks
Outlook: Management expects slightly higher revenues in the next two quarters, reflecting early signs of increased customer capital investment. Gross margins are expected to rise in subsequent quarters due to improved manufacturing efficiencies and higher customer acceptance levels. R&D and SG&A expenses are expected to remain relatively stable or increase modestly in absolute dollars.
Liquidity: The company holds approximately $901.6 million in cash, cash equivalents, and short-term investments. Management believes this is sufficient to support operations and debt obligations (including the maturity of $310 million in 5% Notes in September 2002) for at least the next twelve months.
Risks and Contingencies:
- Revenue Recognition: Adoption of SAB 101 delays revenue recognition until customer acceptance, causing volatility in quarterly results.
- Legal Proceedings: A patent infringement lawsuit filed by Tegal Corporation remains pending; the company believes it will not have a material adverse effect.
- Market Volatility: Results are highly sensitive to the cyclical nature of the semiconductor industry and customer acceptance timing.
- Derivatives: The company holds call and put options on its own stock; significant stock price declines could require cash or share settlements.
Investor Verification Checklist
- Deferred Revenue: Verify the $106.5 million deferred revenue balance and the timing of future recognition under SAB 101 rules.
- Restructuring Reserves: Confirm the utilization of the $20.8 million remaining restructuring reserve (severance and lease obligations) by the end of fiscal 2002.
- Debt Maturity: Assess the plan for the $310 million 5% Convertible Notes maturing in September 2002, including potential conversion or cash settlement.
- Derivative Valuation: Monitor the fair value of equity derivatives ($50.8 million asset) and the impact of stock price fluctuations on non-operating income.
- Inventory Levels: Review the $176.9 million inventory balance against the $24.1 million write-downs to assess remaining obsolescence risk.